DMT

DMT (N,N-dimethyltryptamine) was first synthesised in 1931 by Canadian chemist Richard Manske, though its psychoactive nature was not recognised then. In 1956, Hungarian chemist and psychiatrist Stephen Szára, unable to obtain LSD from Sandoz, self-administered synthetic DMT intramuscularly, documenting intense visual hallucinations and altered consciousness lasting about 30–45 minutes. These self-experiments were the first formal documentation of DMT’s psychoactive effects in humans.

Subsequent discovery of DMT in numerous plants, notably Psychotria viridis (chacruna) and Mimosa hostilis (jurema), linked it to the long-standing Amazonian ayahuasca tradition. Ayahuasca combines a DMT-containing plant with a monoamine oxidase inhibitor, typically Banisteriopsis caapi, making DMT orally active—a pharmacological strategy developed over centuries of indigenous botanical knowledge. DMT was later identified in many other plant species and in several animal tissues.

In the 1960s–1970s, DMT became central to the “endogenous psychotogen” hypothesis, which proposed that abnormal endogenous DMT levels might contribute to psychosis, especially schizophrenia. Researchers confirmed DMT’s presence in human blood and urine, but only at very low concentrations and without clear correlation to psychiatric illness, leaving the hypothesis unresolved. Interest in this line of research waned, though it was occasionally revisited as analytical techniques improved.

A major modern milestone came with Rick Strassman’s work at the University of New Mexico (1990–1995), the first FDA-approved psychedelic clinical studies in decades. Strassman administered intravenous DMT to around 60 volunteers in controlled settings, characterising dose–response relationships, subjective experiences, and physiological effects. His findings, later popularised in the book DMT: The Spirit Molecule, helped re-establish psychedelic research within regulatory frameworks and influenced subsequent psilocybin and MDMA trials.

Contemporary interest focuses on DMT as an ultra-short-acting psychedelic with therapeutic potential. The 2023 acquisition of Small Pharma by Cybin consolidated a leading DMT clinical programme, while several academic groups are exploring extended-state DMT infusions (“DMTx”) designed to sustain the psychedelic state long enough to support structured psychotherapeutic work during the experience.

DMT (N,N-dimethyltryptamine) is a simple tryptamine closely related to serotonin (5-hydroxytryptamine), differing structurally by the addition of two methyl groups on the amine nitrogen. Its primary psychedelic effects are mediated through agonism at the serotonin 5-HT2A receptor, the same principal target implicated in the effects of psilocybin (via psilocin), LSD, and mescaline. However, DMT exhibits a broader receptor pharmacology than most other classic psychedelics.

Beyond 5-HT2A, DMT binds with meaningful affinity to sigma-1 receptors, where it functions as an agonist. The sigma-1 receptor is an intracellular chaperone protein involved in endoplasmic reticulum stress responses, calcium signalling, and neuroprotection. Preclinical evidence suggests that DMT’s sigma-1 activity may enhance neuronal survival under hypoxic conditions and modulate immune responses, potentially via mechanisms that are at least partly independent of its psychedelic effects. This combination of serotonergic psychedelic action and sigma-1 agonism distinguishes DMT from psilocin and LSD and has led to interest in non-psychedelic therapeutic applications.

DMT also interacts with trace amine-associated receptor 1 (TAAR1), the serotonin transporter (SERT), and vesicular monoamine transporter 2 (VMAT2). The functional relevance of these interactions at physiologically achievable concentrations remains under active investigation.

Pharmacokinetically, intravenous (IV) administration of DMT produces a very rapid onset of effects, typically within 30–60 seconds, with peak intensity at about 2–5 minutes and resolution within approximately 15–30 minutes. This ultra-short duration is largely due to rapid metabolism by monoamine oxidase A (MAO-A) in the gut wall, liver, and other tissues. The primary metabolite is indole-3-acetic acid (IAA), formed via oxidative deamination. Because of this efficient first-pass metabolism, orally administered DMT is normally inactive unless combined with an MAO inhibitor (as in ayahuasca), which allows it to reach systemic circulation and the brain.

When smoked or vaporised, DMT bypasses first-pass metabolism, leading to an onset of effects within seconds and a total duration of roughly 10–20 minutes, similar in profile to IV administration. Intramuscular (IM) injection, the route used in Szára’s early human studies, produces a slightly slower onset (around 2–5 minutes) and a modestly longer duration (approximately 30–45 minutes) compared with IV dosing.

DMT appears acutely safe in controlled clinical settings, with adverse effects that are typically transient and self-limiting over its brief psychoactive window.

Acute effects

• Cardiovascular:Moderate, short-lived increases in heart rate and blood pressure, peaking within minutes of administration and resolving as psychoactive effects wane. These changes are generally less prolonged than those seen with longer-acting psychedelics such as LSD or psilocybin.
• Psychological:Rapid onset of intense perceptual alterations, including vivid visual phenomena, entity encounters, ego dissolution, and strong emotional responses. The abruptness and intensity can be disorienting and may precipitate anxiety or panic, especially in unprepared individuals or non-controlled environments.
• Autonomic:Nausea (more prominent with ayahuasca due to additional plant alkaloids), mydriasis, and occasional tremor.

Safety advantages

A major safety advantage is the brevity of effect: for IV or smoked DMT, the core experience typically resolves within 15–30 minutes. This short duration limits the time during which intensive psychological support is required and may reduce the likelihood of prolonged adverse psychological reactions compared with longer-acting psychedelics.

Dependence and tolerance

• No established physical dependence or withdrawal syndrome has been documented.
• Animal data suggest low reinforcing potential, and clinical reports do not indicate a pattern of compulsive use or addiction.
• Tolerance (tachyphylaxis) develops rapidly with repeated dosing, consistent with other serotonergic psychedelics.

Primary clinical safety concerns

• Psychological vulnerability:Individuals with a personal or family history of psychotic disorders may be at higher risk for destabilising or prolonged psychological reactions, as with other 5-HT2A agonist psychedelics.
• Cardiovascular risk:Patients with uncontrolled hypertension or significant cardiovascular disease should generally be excluded due to acute sympathomimetic effects.
• Drug interactions:
• Concomitant serotonergic agents (e.g., SSRIs, SNRIs, MAOIs) raise theoretical risks, including serotonin toxicity.
• MAO inhibition (as in ayahuasca) prolongs and intensifies DMT’s effects, creating a distinct and more prolonged risk profile compared with isolated DMT.

Long-term considerations

Long-term safety data for repeated exogenous DMT administration remain limited. The fact that DMT is endogenously present in human tissues does not, by itself, demonstrate the safety of pharmacological-dose administration, and further systematic research is needed to characterise chronic or repeated-use effects.

Clinical trial data for DMT are considerably more limited than for psilocybin, MDMA, or ketamine, reflecting its earlier stage of therapeutic development. The evidence base consists primarily of pharmacological characterisation studies, a small number of controlled trials, and early-phase therapeutic programmes.

Rick Strassman's studies at the University of New Mexico (1990–1995) remain foundational. In a series of dose-escalation and fixed-dose studies involving approximately 60 healthy volunteers, Strassman characterised the subjective, physiological, and neuroendocrine effects of intravenous DMT across a range of doses (0.05–0.4 mg/kg). These studies established that DMT produces dose-dependent increases in subjective intensity, heart rate, blood pressure, cortisol, prolactin, and growth hormone, with effects peaking at 2–5 minutes and resolving within 30 minutes. While not designed as therapeutic trials, they provided the pharmacological foundation for all subsequent clinical work.

The Imperial College London DMT research programme, led by Christopher Timmermann and Robin Carhart-Harris, has conducted controlled studies examining the phenomenology and neural correlates of DMT in healthy volunteers using EEG and fMRI neuroimaging. These studies have characterised DMT's effects on brain network connectivity, entropy measures, and subjective experience, contributing to the neuroscientific understanding of DMT's mechanism but not directly testing therapeutic efficacy.

The most therapeutically relevant programme was initiated by Small Pharma (subsequently acquired by Cybin in 2023). Their Phase I/IIa trial (SPL026) investigated intravenous DMT (SPL026) combined with psychotherapy in patients with major depressive disorder. Preliminary results suggested rapid antidepressant effects following a single DMT-assisted therapy session, with improvements observed at 24 hours and sustained at 7 days in some participants. The Cybin-acquired programme (now designated CYB004 for the deuterated DMT formulation) is advancing through Phase II development.

Extended-state DMT infusion ("DMTx") protocols are being explored at institutions including Imperial College London, using continuous IV infusion to maintain the psychedelic state for extended periods (30–60+ minutes) rather than the standard bolus-induced 15-minute experience. These studies aim to determine whether prolonged DMT exposure can facilitate deeper psychotherapeutic engagement, similar to the multi-hour sessions enabled by psilocybin. This approach is still in early feasibility and safety assessment phases.

DMT's clinical development is anchored on the hypothesis that its ultra-short psychedelic action could support a more scalable, economically efficient model of psychedelic-assisted therapy than longer-acting agents like psilocybin.

Short-session advantage

A 20–30 minute DMT session, versus 6–8 hours for psilocybin, could materially change care delivery:

• Staffing efficiency:fewer therapist hours per session and potential for higher throughput per clinician.
• Facility utilisation:reduced room occupancy time and ability to treat multiple patients per room per day.
• Patient burden:less time off work, shorter clinic visits, and potentially improved acceptability and adherence.

This operational and economic profile is the main driver of current commercial and clinical interest in DMT.

Key uncertainties

The pivotal unknown is whether such brevity can deliver comparable therapeutic efficacy to longer-acting psychedelics:

• Psilocybin offers a prolonged period for emotional processing, insight generation, and in-session integration, plus a post-acute "afterglow" that may support behaviour change.
• It is not yet established whether DMT's compressed experience can reliably reach similar psychological depth or sustain durable clinical outcomes.

Resolving this efficacy–duration trade-off is central to DMT's value proposition.

Extended-state infusion (DMTx)

DMTx—continuous IV infusion to maintain the psychedelic state for 30–60+ minutes—aims to blend controllability with a longer therapeutic window:

• Rapid offset remains available by stopping the infusion.
• Clinicians could, in principle,titrate both intensity and duration in real time.

Key open questions include:

• Safety and tolerability of prolonged DMT exposure.
• Effects on neuroplasticity and whether extended dosing alters risk–benefit compared with bolus administration.

These require structured dose-finding and safety studies before DMTx can be widely adopted.

Indication landscape

• Lead indication:Depression, especially treatment-resistant depression, in line with broader psychedelic development.
• Evidence to date:Early-phase data (e.g., Small Pharma/Cybin) show preliminary antidepressant signals, but no definitive Phase II/III efficacy data yet.
• Other indications:Anxiety disorders, PTSD, and substance use disorders remain hypothetical targets; controlled trials in these populations have not yet been completed.

Development timeline

DMT-assisted therapy lags psilocybin by roughly 3–5 years in clinical maturity. Under optimistic assumptions (positive Phase II data, smooth development):

• Pivotal Phase II/III trials would need to be completed over the next several years.
• Regulatory submissions are unlikely before ~2028–2030 at the earliest.

Overall, DMT's promise hinges on demonstrating that its operational advantages do not come at the cost of meaningful, durable therapeutic benefit.

DMT is currently subject to some of the most restrictive drug control regimes worldwide. In the United States, it is a Schedule I controlled substance under the Controlled Substances Act, indicating a high potential for abuse, no currently accepted medical use, and a lack of accepted safety under medical supervision. Comparable prohibitions exist in many other jurisdictions: in the UK, DMT is a Class A drug under the Misuse of Drugs Act; across the EU it is generally controlled through national laws implementing the UN Convention on Psychotropic Substances; and similar strict controls are in place throughout most of Asia and Latin America.

A narrow and notable exception concerns ayahuasca, a traditional Amazonian brew containing DMT, when used in specific religious contexts. In the United States, the Supreme Court’s decision in Gonzales v. O Centro Espírita Beneficente União do Vegetal (2006) held that the Religious Freedom Restoration Act protects the sacramental use of ayahuasca by the UDV church. Related exemptions have been granted to Santo Daime churches in the US and in several other countries. These exemptions are tightly circumscribed: they apply to defined religious practices and do not legalise isolated DMT, non-sacramental ayahuasca, or any non-religious use.

No DMT-based medicine has been approved for therapeutic use in any country. Nonetheless, DMT is under active investigation in clinical research, particularly in psychiatry. In the US, studies are being conducted under FDA Investigational New Drug (IND) authorisations, including trials in depression. Programmes such as Cybin’s CYB004 (a deuterated DMT analogue) and earlier Small Pharma studies have proceeded within standard regulatory frameworks for clinical trials, involving ethics approvals, controlled substance handling licences, and adherence to good clinical practice.

If DMT-assisted therapy were to move toward clinical adoption, its regulatory trajectory would likely mirror that of psilocybin: rigorous phase II and III randomised controlled trials to establish safety and efficacy, followed by submission of a New Drug Application (NDA) or equivalent dossier to regulators. Because DMT is Schedule I (or equivalent) in most jurisdictions, any approved medical product would almost certainly require rescheduling or the creation of specific medical-use exemptions, analogous to the anticipated pathway for psilocybin-based therapies.

Australia illustrates the current developmental gap between DMT and other psychedelics. The Therapeutic Goods Administration (TGA) rescheduled psilocybin and MDMA in 2023 to permit tightly controlled use by authorised psychiatrists for certain treatment-resistant conditions. However, this reclassification has not been extended to DMT, reflecting its earlier stage of clinical development and the absence of a comparable evidence base at this time.

DMT’s commercial case is built on the idea that its much shorter psychedelic sessions could lower treatment costs, improve clinic throughput, and make psychedelic-assisted therapy more scalable than psilocybin-based approaches.

Cybin is the leading commercial player after acquiring Small Pharma in 2023. Its key DMT-related asset is CYB004, a deuterated DMT analogue delivered via inhalation. This route is intended to be more practical and standardisable than IV infusion. Deuteration (substituting hydrogen with deuterium) is designed to slightly prolong the drug’s effect and enhance metabolic stability while preserving DMT’s core pharmacology. CYB004 is being advanced in parallel with CYB003, Cybin’s deuterated psilocybin analogue, as a flagship program.

Beyond Cybin, the DMT field is relatively thin compared with psilocybin. Algernon Pharmaceuticals is developing DMT for stroke based on sigma-1 receptor–mediated neuroprotective mechanisms, representing a non-psychiatric indication. A handful of early-stage biotechs are also working on DMT formulations and analogues, but overall competitive intensity is far lower than in psilocybin, where many companies are targeting similar psychiatric indications.

DMT-assisted therapy’s commercial success will hinge on several proof points:

• Phase II/III data must show efficacy that is at least non-inferior to psilocybin.
• Real-world practice must confirm that shorter sessions translate into meaningful cost and capacity advantages.
• Payers must be willing to reimburse a second psychedelic modality even if psilocybin is already approved and established.

If DMT can clearly demonstrate a differentiated profile—especially around session efficiency and operational advantages—it could secure a substantial share of the psychedelic-assisted therapy market. Without such differentiation, it may struggle to compete against psilocybin’s earlier market entry and broader clinical evidence base.

DMT's ultra-brief yet intense psychedelic action positions it as a potentially more scalable and logistically feasible therapeutic compared to longer-acting psychedelics, but its compressed timeline raises open questions about therapeutic depth, integration, and comparative efficacy.

Mechanistically, DMT, psilocybin, and LSD are all primarily 5-HT2A receptor agonists, yet DMT's pharmacokinetics are markedly distinct. When administered intravenously or via inhalation, DMT produces rapid onset and clearance, with full mystical-type experiences unfolding and resolving within roughly 15–30 minutes. This contrasts sharply with psilocybin's 4–6 hour and LSD's 8–12 hour durations. The key driver of this brevity is extensive first-pass metabolism by monoamine oxidase A (MAO-A), which rapidly degrades DMT unless MAO is inhibited.

Clinically, this short action window enables a therapeutic model centered on brief, contained dosing sessions that could fit into standard appointment slots. A DMT-assisted treatment might require under an hour of total clinic time, including preparation and recovery, substantially reducing therapist hours, room occupancy, and overall cost per session. By comparison, psilocybin protocols often demand 6–8 hours of continuous therapist presence, and MDMA-assisted therapy can extend beyond 8 hours, creating significant resource and staffing burdens.

The same brevity, however, introduces potential limitations. Longer psilocybin or MDMA sessions allow for gradual onset, extended introspection, and in-session therapeutic processing—time for emotions, memories, and insights to arise, be explored, and partially integrated with therapist support. Compressing the entire psychedelic arc into ~20 minutes may constrain the opportunity for real-time psychotherapeutic work, shifting more of the integration burden to pre- and post-session therapy. This concern is motivating the development of extended-state DMT (DMTx) protocols, in which continuous or carefully titrated IV infusion maintains a stable psychedelic state over a longer period. DMTx aims to merge DMT's controllable pharmacology (rapid on/off, adjustable level) with the sustained experiential window more typical of psilocybin or LSD.

Relative to ketamine—the only widely legal psychedelic-adjacent treatment—DMT offers a qualitatively different experiential and pharmacological profile. Ketamine acts primarily as an NMDA receptor antagonist, producing dissociative states often characterized by detachment from body and self, with less consistently elaborate visual phenomenology. DMT, via serotonergic mechanisms, reliably elicits vivid, immersive visionary experiences and profound alterations in perceived reality. Whether these phenomenological and mechanistic differences translate into meaningfully different clinical outcomes (e.g., durability of antidepressant effects, impact on trauma processing, or changes in meaning-making and worldview) remains an empirical question that will require direct comparative trials.

In the ayahuasca context, DMT's profile changes substantially. Oral DMT co-administered with MAO inhibitors (typically harmala alkaloids) yields a 4–6 hour experience, more similar in duration to psilocybin but with a distinct pharmacological and subjective signature. Here, MAO inhibition prevents rapid DMT breakdown, allowing sustained systemic exposure. From a development standpoint, isolated IV DMT and ayahuasca-like oral formulations represent two divergent strategies built around the same core molecule. IV DMT emphasizes precision, standardization, and operational efficiency: tightly controlled dosing, predictable onset and offset, and easier integration into conventional medical workflows. Ayahuasca-style approaches emphasize a more extended, often ritualized experience that may foster different forms of psychological processing and meaning-making but pose greater challenges for standardization, regulatory approval, and large-scale clinical deployment.

Overall, DMT's unique combination of classical psychedelic phenomenology with extremely short duration creates both opportunities and uncertainties. It offers a compelling route to more accessible, clinic-friendly psychedelic therapy models, but the field still needs robust data on how its compressed experiential arc compares—clinically and existentially—to the longer journeys afforded by psilocybin, LSD, MDMA, and ayahuasca.